Home>>Infectious Disease>> Viral Diseases>> Coronaviruses>>GK241

GK241

Catalog No.GC52315

An sPLA2 (Type IIA) inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

GK241 Chemical Structure

Cas No.: 1899930-93-8

Size Price Stock Qty
1 mg
$76.00
In stock
5 mg
$342.00
In stock
10 mg
$605.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

GK241 is a secretory phospholipase A2 (sPLA2) (Type IIA) inhibitor (IC50s = 0.143 and 0.068 µM for the human and mouse enzymes, respectively).1,2 It inhibits IL-1β-induced production of prostaglandin E2 in isolated rat renal mesangial cells when used at concentrations of 3 and 10 µM.3 GK241 also inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), also known as 3C-like protease (3CLpro; IC50 = 24 µM).1

1.Theodoropoulou, M.A., Koutoulogenis, G.S., Zhang, L., et al.Identification of a dual inhibitor of secreted phospholipase A2 (GIIA sPLA2) and SARS-CoV-2 main proteasePharmaceuticals (Basel)15(8)961(2021) 2.Vasilakaki, S., Barbayianni, E., Leonis, G., et al.Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulationsBioorg. Med. Chem.24(8)1683-1695(2016) 3.Vasilakaki, S., Barbayianni, E., Magrioti, V., et al.Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cellsBioorg. Med. Chem.24(13)3029-3034(2016)

Reviews

Review for GK241

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GK241

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.